Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | Raf-1 proto-oncogene, serine/threonine kinase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | TKL/RAF/RAF protein kinase | Get druggable targets OG5_130459 | All targets in OG5_130459 |
Schistosoma mansoni | serine/threonine protein kinase | Get druggable targets OG5_130459 | All targets in OG5_130459 |
Loa Loa (eye worm) | raf kinase | Get druggable targets OG5_130459 | All targets in OG5_130459 |
Schistosoma japonicum | ko:K04365 B-Raf proto-oncogene serine/threonine-protein kinase, putative | Get druggable targets OG5_130459 | All targets in OG5_130459 |
Echinococcus granulosus | raf serine:threonine protein kinase | Get druggable targets OG5_130459 | All targets in OG5_130459 |
Brugia malayi | Raf kinase | Get druggable targets OG5_130459 | All targets in OG5_130459 |
Echinococcus multilocularis | raf serine:threonine protein kinase | Get druggable targets OG5_130459 | All targets in OG5_130459 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | glutamate receptor, ionotrophic, AMPA 3 | 0.0257 | 0.606 | 0.5659 |
Loa Loa (eye worm) | glutamate receptor 1 | 0.021 | 0.3427 | 0.5467 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0235 | 0.4864 | 0.5 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0235 | 0.4864 | 0.5 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0235 | 0.4864 | 0.5 |
Loa Loa (eye worm) | glutamate receptor 2 | 0.021 | 0.3427 | 0.5467 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0257 | 0.606 | 0.5659 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0257 | 0.606 | 0.5659 |
Echinococcus granulosus | glutamate receptor 2 | 0.0257 | 0.606 | 0.5659 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0262 | 0.6339 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0257 | 0.606 | 0.5659 |
Echinococcus multilocularis | glutamate (NMDA) receptor subunit | 0.021 | 0.3427 | 0.2758 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0235 | 0.4864 | 0.5 |
Echinococcus granulosus | raf serine:threonine protein kinase | 0.0262 | 0.6339 | 0.5967 |
Echinococcus granulosus | glutamate receptor ionotrophic AMPA 3 | 0.0257 | 0.606 | 0.5659 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0235 | 0.4864 | 0.5 |
Loa Loa (eye worm) | raf kinase | 0.026 | 0.6268 | 1 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0257 | 0.606 | 0.5659 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0327 | 1 | 1 |
Echinococcus multilocularis | raf serine:threonine protein kinase | 0.0262 | 0.6339 | 0.5967 |
Chlamydia trachomatis | glutamine binding protein | 0.0235 | 0.4864 | 0.5 |
Echinococcus multilocularis | glutamate receptor 2 | 0.021 | 0.3427 | 0.2758 |
Echinococcus granulosus | glutamate NMDA receptor subunit | 0.021 | 0.3427 | 0.2758 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0327 | 1 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0257 | 0.606 | 0.5659 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0257 | 0.606 | 0.5659 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0257 | 0.606 | 0.5659 |
Brugia malayi | Raf kinase | 0.0253 | 0.5829 | 1 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0257 | 0.606 | 0.904 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 650 nM | Inhibition of Raf-1 | ChEMBL. | 18947905 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.